The combined use of proton pump inhibitors and antibiotics as risk factors for Clostridium difficile infection
Daniel S. Kassavin A C , David Pham A , Linda Pascarella A , Kuo Yen-Hong B and Michael A. Goldfarb A
+ Author Affiliations
- Author Affiliations
A Monmouth Medical Center, 300 2nd Ave, Long Branch, NJ 07740, USA.
B Jersey Shore Medical Center, 1945 Route 33, Neptune, NJ 07753, USA.
C Corresponding author. Email: dkassavin@gmail.com
Healthcare Infection 18(2) 76-79 https://doi.org/10.1071/HI12039
Submitted: 27 July 2012 Accepted: 17 December 2012 Published: 24 April 2013
Abstract
Purpose: A review of the incidence of Clostridium. difficile infection (CDI) at our hospital was performed due to the morbidity of CDI in its fulminate form, reports of the increased incidence of CDI in the United States and the increased use of medications associated with its onset.
Methods: The study was retrospective and took place over a 9-month period, from 1 January 2009 through 30 September 2009.
Results: There were 88 cases of CDI in the course of the review which amounted to 5.1 infections per 1000 patient hospital admissions. The percentage of overall admissions that were prescribed antibiotics and proton pump inhibitors (PPI), PPI alone or antibiotics alone were 17.1%, 15.5% and 24.3%, respectively. Of all cases of CDI, 59.1% of patients were on both a PPI and antibiotic, 9.1% were on a PPI alone and 13.6% were on an antibiotic alone. Patients on both proton pump inhibitors and antibiotics had an odds ratio of 8.30 (P < 0.0001) compared with patients on neither of these medications.
References
[1] Jarvis WR, Schlosser J, Jarvis AA, Chinn RY. National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control 2009; 37 263–70.| National point prevalence of Clostridium difficile in US health care facility inpatients, 2008.Crossref | GoogleScholarGoogle Scholar | 19278754PubMed |
[2] Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31 431–55.
| Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA).Crossref | GoogleScholarGoogle Scholar | 20307191PubMed |
[3] Famularo G, Gasbarrone L, De Simone C. Proton pump inhibitors and the risk for Clostridium difficile infection. JAMA 2009; 302 31–2.
| Proton pump inhibitors and the risk for Clostridium difficile infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXotFGrsrg%3D&md5=6ee93750a84f5885f82111099e8678c3CAS | 19567433PubMed |
[4] Howell MD, Novack V, Grgurich P,, Soulliard D, Novack L, Pencina N, et al Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170 784–90.
| Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection.Crossref | GoogleScholarGoogle Scholar | 20458086PubMed |
[5] Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170 772–8.
| Proton pump inhibitors and risk for recurrent Clostridium difficile infection.Crossref | GoogleScholarGoogle Scholar | 20458084PubMed |
[6] Zilberberg MD, Shorr AF, Koller MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis 2008; 14 929–31.
| Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000–2005.Crossref | GoogleScholarGoogle Scholar | 18507904PubMed |
[7] Zilberberg MD. Assessment of reporting bias for Clostridium difficile hospitalizations, United States. Emerg Infect Dis 2008; 14 1334
| Assessment of reporting bias for Clostridium difficile hospitalizations, United States.Crossref | GoogleScholarGoogle Scholar | 18680680PubMed |
[8] Zilberberg MD. Clostridium difficile-related hospitalizations among US adults 2006. Emerg Infect Dis 2009; 15 122–4.
| Clostridium difficile-related hospitalizations among US adults 2006.Crossref | GoogleScholarGoogle Scholar | 19116073PubMed |
[9] Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002; 23 137–40.
| Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals.Crossref | GoogleScholarGoogle Scholar | 11918118PubMed |
[10] Miller MA, Gravel D, Mulvey M, McGeer A, Simor A, Taylor G. et al. Surveillance for nosocomial Clostridium difficile associated diarrhea (N-CDAD) within acute-care hospitals in Canada: results of the 2005 nosocomial infections surveillance program (CNISP) study shows escalating mortality. In: Proceedings of the 16th Annual Scientific Meeting of the Society for Healthcare. Epidemiology of America; 2006 March 18–21; Chicago, IL.
[11] Shannon-Lowe J, Matheson NJ, Cooke FJ, Aliyu SH. Prevention and medical management of Clostridium difficile infection. BMJ 2010; 340 c1296
| Prevention and medical management of Clostridium difficile infection.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC3c7otFejtg%3D%3D&md5=c7d49c37f40b1cd4a29bd96df9386bc3CAS | 20228142PubMed |
[12] Pham CQ, Regal RE, Bostwick TR, Knauf KS.. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacol 2006; 40 1261–6.
| Acid suppressive therapy use on an inpatient internal medicine service.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28XptVehsr8%3D&md5=6d3f3a9b815faf5a15e754f284212873CAS |
[13] Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294 2989–95.
| Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2MXhtleltL7P&md5=be223f972973bde995d623e32e03c989CAS | 16414946PubMed |
[14] Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000; 95 3118–22.
| 1:STN:280:DC%2BD3M%2FnsFKjsw%3D%3D&md5=74fda7d6e3a5570e9b4bd025db0cfdaeCAS | 11095327PubMed |
[15] Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007; 45 992–8.
| Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents.Crossref | GoogleScholarGoogle Scholar | 17879913PubMed |